Compare Las Vegas Sands Corp. (LVS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Novavax Inc — how do they compare? Las Vegas Sands Corp. trades at $45.5 (market cap $30.36B), while Novavax Inc trades at $8.06 (market cap $1.30B). The key difference: Las Vegas Sands Corp. is far larger — about 23.4× Novavax Inc's market cap, and Las Vegas Sands Corp. pays a 2.4% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| LVS | NVAX | |
|---|---|---|
Market Cap | $30.36B | $1.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $11.19 |
52-Week Low | $44.78 | $6.22 |
Enterprise Value | $42.75B | $800.50M |
Dividend Yield | 2.4% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
